DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and ...

DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...

For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is ...

DexCom Inc (NASDAQ:DXCM) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the January 28 closing, DexCom Inc. (NASDAQ:DXCM) had highly bullish sentiment ...

DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...

The medical device specialist lagged the market, and even with a bit of a rebound toward the second half of 2025, shares are ...

The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more affordable way to monitor their blood sugar. The Stelo CGM is meant to give Type 2 diabetics who don’t need insulin a more ...

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

DexCom's Q2 earnings report was disastrous, revealing internal sales channel issues and competitive pressures, leading to a Hold rating and lowered price targets. The company's reliance on channel ...

DexCom is a leading healthcare stock that has seen significant growth, with shares returning close to 1,400% in the past decade. DXCM stock has faced resistance and is currently 37% below its all-time ...

Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with Type 2 diabetes and your fit-fluencer friend. Jake Leach, who took over as Dexcom CEO today, wants ...

Shares of DexCom recently soared after the company reported better-than-expected third-quarter results. DexCom markets constant blood-glucose monitors for diabetic patients, and its next-generation ...